Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age

AstraZeneca

Status and phase

Completed

Phase 3

Conditions

Pediatric Hypertension

Treatments

Drug: candsartan cilexetil

Study type

Interventional

Funder types

Industry

Identifiers

NCT00244634

261A

D2451C00261

Details and patient eligibility

About

Study 261A is a dose-ranging and safety study of candesartan cilexetil. It is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with a 4 week treatment period in hypertensive pediatric subjects.

Subjects undergo a screening evaluation, then a 1-week, single-blind, placebo run-in after which eligible subjects are allocated to receive 1 of 3 dose levels of candesartan cilexetil or placebo. The study includes 2 panels based on subject weight.

The primary efficacy analysis is based on the intent-to-treat population and tests for slope = 0 in a linear regression model with change in sitting systolic blood pressure as the dependent and non-zero dose pooled across weight panels as the independent variable. For subjects without a Double-Blind Week 4 blood pressure determination, carrying the last value forward assigns the value.

Additional analyses will include data pooled from a similar dose ranging study conducted in children 1 to < 6 years of age.

Sex

All

Ages

6 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female ages 6 to < 17 years-of-age after parent or guardian's signing of informed consent.

Subjects with hypertension that is either:

Diagnosed and untreated with a mean sitting systolic and/or diastolic blood pressure ≥ 95th percentile and ≤ 20 mm Hg (systolic) and/or 10 mm Hg (diastolic) above the 95th percentile at randomisation based on height-adjusted charts for age and gender; or
Previously diagnosed and currently treated with mean sitting systolic blood pressure and/or diastolic blood pressure ≥ 95th percentile and ≤ 20 mm Hg (systolic) and/or 10 mm Hg (diastolic) above the 95th percentile at randomisation (off treatment) based on height-adjusted charts for age and gender.

Females of childbearing potential (post-menarche) must have a negative urine pregnancy test prior to randomization and adhere to a pregnancy prevention method (abstinence, barrier method plus spermicidal foam, oral, or implanted contraceptive).

A signed informed consent by a parent or a legal guardian and an assent form signed by the subject (if applicable).

Exclusion criteria

Any situation, clinical condition or laboratory abnormality that, in the opinion of the investigator or sponsor, may interfere with the subject's participation in the study or would pose a significant risk to the subject or interfere with the assessment of safety and efficacy endpoints.
Hypertension secondary to coarctation of the aorta, pheochromocytoma, hyperthyroidism, Cushing's syndrome, or medications (eg: corticosteroids).
Known history of bilateral renal artery stenosis, unilateral renal artery stenosis or a renal transplant.
Glomerular filtration rate < 50 mL/min based on an estimated value using the Schwartz Formula.
Nephrotic syndrome not in remission.
Insulin dependent diabetes mellitus.
Known bleeding, coagulation, or platelet disorder that could interfere with blood sampling.
Clinically significant valvular heart disease.
Clinical diagnosis of heart failure.
Clinically significant arrhythmia (eg, any arrhythmia requiring medical therapy or that causes symptoms).
Second or third degree AV block.
Pregnant or breast-feeding an infant.
Impaired liver function defined as either acute liver disease or chronic liver disease with persistent liver enzyme values greater than 1½ times the upper limit of the reference range for AST or ALT.
Known hypersensitivity to ARBs.
Unable to be off antihypertensive medication (diuretics, beta blockers, ACE Inhibitors, etc) for 6-weeks.
Inability to discontinue medications which may contribute to elevated blood pressure e.g. systemic corticosteroids.
Currently using, or used within 14 days prior to receiving double-blind medication, any concomitant medications which in the opinion of the investigator could negatively affect the subject.
Unable or unwilling to comply with the study requirements including blood sampling and swallowing study drug tablets.
Received an investigational agent within 30 days prior to receiving study medication.
Alcohol or drug abuse.